Compare MIND & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIND | ALGS |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2M | 34.6M |
| IPO Year | 1997 | 2020 |
| Metric | MIND | ALGS |
|---|---|---|
| Price | $4.08 | $4.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $52.38 |
| AVG Volume (30 Days) | ★ 55.2K | 35.4K |
| Earning Date | 12-08-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.77 | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $42,675,000.00 | $2,186,000.00 |
| Revenue This Year | N/A | $1,562.10 |
| Revenue Next Year | $73.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.63 | $3.98 |
| 52 Week High | $14.50 | $13.69 |
| Indicator | MIND | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 40.10 | 36.83 |
| Support Level | $3.63 | N/A |
| Resistance Level | $4.78 | $6.91 |
| Average True Range (ATR) | 0.24 | 0.35 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 6.10 | 21.84 |
MIND Technology Inc provides technology and solutions for exploration, survey, and defense applications in oceanographic, hydrographic, defense, seismic, and security industries. The company operates in single segment namely, Seamap which provides services and products, including engineering, repairs and software licensing, utilized in marine exploration, marine survey and maritime security for marine survey companies, seismic survey contractors, research institutes, non-military government organizations and operators of port facilities and other offshore installations. The company generates more revenue from Seamap Marine Products. The company's geographical segments include the United States; China, Norway; Turkey; Singapore; and Canada & Other.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.